Targets targeted by Osimertinib (Tagressa)

Osimertinib (Tagrisso) is a targeted therapy drug that mainly targets specific molecular targets in non-small cell lung cancer (NSCLC). Its main target is the epidermal growth factor receptor (EGFR). EGFR is a receptor tyrosine kinase located on the cell surface. It belongs to the receptor tyrosine kinase family and is involved in regulating important biological processes such as cell growth, differentiation and survival.

Under normal circumstances, EGFR activates intracellular signaling pathways by binding to its ligands, such as epidermal growth factor (EGF), thereby promoting cell proliferation and survival. However, in some patients with non-small cell lung cancer, the EGFR gene is mutated, resulting in abnormally enhanced activity of EGFR, thereby promoting abnormal proliferation and growth of tumor cells.

The mechanism of action of osimertinib (Tagressa) is closely related to this. It is a highly selective EGFRtyrosine kinase inhibitor that blocks abnormal signaling pathways by binding to EGFR and inhibiting its activity, thereby inhibiting the growth and spread of tumor cells. Compared with traditional EGFRinhibitors, osimertinib (Tagrisso)has higher selectivity and stronger anti-tumor activity, especially for some NSCLC patients with specific EGFR mutations, such as T790M mutations.

The T790Mmutation is one of the main causes of resistance to other EGFR inhibitors in NSCLC patients. However, osimertinib (Tagrisso) is able to effectively overcome this resistance because it more effectively inhibits the growth of tumor cells and displays higher anti-tumor activity in tumor cells targeting the T790M mutation.

Therefore,osimertinib (Tagrisso) as a drug that targets EGFR’s targeted therapy drugs have shown significant efficacy in patients with non-small cell lung cancer. It provides an effective treatment option for NSCLC patients with EGFR mutations, resulting in better treatment outcomes and quality of life.